Search

The correct diagnosis of chronic kidney disease (CKD) depends on several equations to estimate the glomerular filtration rate (GFR), such as Cockroft-Gault (CG), MDRD and CKD-EPI. The objective was to estimate and compare the GFR obtained by different equations, using data from patients seen in a public clinical analysis laboratory (LRR). A retrospective, cross-sectional, descriptive study was carried out, using data from 7828 patients and estimating the GFR values using the CG equations with real weight (CG1) and ideal weight (CG2), MDRD and CKD-EPI for comparison with the LRR results (cLRR group), using ANOVA and both Student t-test and Bonferroni post-test, and compared with international criteria for CKD. The GFR values are statistically different. The CG1 group is similar to cLRR. All equations (except CG2) appear to produce convergent results for GFR ≥ 60 mL/min. When GFR ≤ 29.0 mL/min, the cLRR frequency is the same as that of CG1; however, compared with the data obtained by the other equations, the patients’ number is considerably higher, which suggests a refinement in the way of classifying CKD. As for the intermediate GFR values (30-59 mL/min), indicative of mild-moderate and moderate-severe GFR reduction, the CG2 data fits 31.5% of the patients, against 8-10.4% of the other equations. Thus, the estimate of GFR varies according to the chosen equation, especially for GFR

The study aims to develop activities for therapeutic monitoring of oral busulfan in patients undergoing heterologous stem-cell transplantation (HSCT) through the identification and determination of plasma busulfan. It was used HPLC-PDA Shimadzu C18 column (150 mm x 4 mm), methanol/water/acetonitrile (65:20:15, v/v/v), flow rate 1 mL min-1, UV λ=276 nm, analysis time 17 min; derivatization with sodium diethylcarbamate, extraction with ethyl acetate; linear calibration curve over the range of 200-5000 ng ml-1. The average relative recovery of the controls was 89% ± 0.04 (QCH=86%; QCM=87%; QCL=93%), and the internal standard (IS) was 74%±0.47. The mean absolute recovery of the controls was 114±0.03% (QCH=111%, QCM=118%; QCL=113%), and the IS was 102±2.5%. The lower limits of detection and quantification obtained were respectively 200 ng ml-1 and 40 ng.mL-1. The linearity was evaluated by calibration curve (200-5000 ng.mL-1) (r=0.998, r=0.994, r=0.998). The repeatability (intracorrida) resulted in 1.25% -11.25% and intermediate precision (intercorrida) resulted in 2.17% -10.71%. The accuracy was found to be 89.61% -102.18%. The short-term stability of the solutions and samples extracted was 6.25% and 3.18% for QCL, 7.54% and 2.4% for QCH, and 4.13% and 13.17% for IS, respectively. The stability of freeze-thaw cycles extracted samples and the solutions was 3.64% and 2.53% for QCL, 9.09% and 5.65% and QCH to 4.82% and 10.32% for IS, respectively. It was concludefd that it was possible to describe a technique for determining the busulfan in plasma by HPLC-PDA, settling their validation parameters for therapeutic drug monitoring purposes. Se optimizó un método para la monitorización plasmática de busulfán en pacientes sometidos a trasplante de células madre hematopoyéticas (TCMH). HPLC-PDA Shimadzu, columna C18 (150 mm x 4 mm), metanol/agua/acetonitrilo (65:20:15, v/v/v), se usó un flujo de 1 ml min-1; UV λ = 276 nm, tiempo de análisis 17 min; derivatización con dietilcarbamato de sodio, extracción con acetato de etilo; curva de calibración lineal de 200-5000 ng.mL-1. La recuperación relativa de los controles fue de 89% ± 0,04 (CQA = 86%; CQM = 87%; CQB = 93%) y la del EI (estándar interno) fue de 74% ± 0,47. La recuperación absoluta de los controles fue 114% ± 0.03 (CQA = 111%; CQM = 118%; CQB = 113%), y la del EI fue 102% ± 2.5. Los límites inferiores de cuantificación y detección obtenidos fueron, respectivamente, 200 ng.mL-1 y 40 ng.mL-1. La linealidad se analizó mediante la curva de calibración (200–5000 ng.mL-1) (r = 0,998). La repetibilidad (intra-análisis) fue de 1,25% -11,25% y la precisión intermedia (entre análisis), 2,17% -10,71%. La precisión encontrada fue de 89,61% -102,18%. La estabilidad a corto plazo de las muestras y soluciones extraídas fue de 6.25% y 3.18% para CQB, 7.54% y 2.4% para CQA y 13.17% y 4.13% para EI, respectivamente. La estabilidad de los ciclos de congelación y descongelación de las muestras y soluciones extraídas fue de 3.64% y 2.53% para CQB, 9.09% y 5.65% para CQA y 10.32% y 4.82% para EI, respectivamente. Así, fue posible validar una técnica para la determinación de busulfán en plasma por HPLC-PDA, adecuada para monitorización terapéutica de los pacientes. Otimizou-se método para monitoração plasmática de bussulfano em pacientes submetidos a transplante de células-tronco hematopoiéticas (TCTH). Utilizou-se HPLC-PDA Shimadzu, coluna C18 (150 mm x 4 mm), metanol/água/acetonitrila (65:20:15, v/v/v), fluxo 1 mL min-1; UV λ = 276 nm, tempo de análise de 17 min; derivatização com dietilcarbamato de sódio, extração com acetato de etila; curva de calibração linear de 200-5000 ng mL-1. A recuperação relativa dos controles foi de 89%±0,04 (CQA = 86%; CQM = 87%; CQB = 93%) e a do PI (padrão interno) foi de 74%±0,47. A recuperação absoluta dos controles foi de 114%±0,03 (CQA = 111%; CQM = 118%; CQB = 113%), e a do PI foi de 102%±2,5. Os limites inferiores de quantificação e detecção obtidos foram, respectivamente, de 200 ng mL-1 e 40 ng mL-1. A linearidade foi analisada pela curva de calibração (200–5000 ng.mL-1) (r = 0,998). A repetibilidade (intracorrida) foi de 1,25%-11,25%, e a precisão intermediária (intercorrida), 2,17%-10,71%. A exatidão encontrada foi de 89,61%-102,18%. A estabilidade de curta duração de amostras extraídas e das soluções foi de 6,25% e 3,18% para CQB, 7,54% e 2,4% para CQA e 13,17% e 4,13% para PI, respectivamente. A estabilidade de ciclos de congelamento e descongelamento de amostras extraídas e das soluções foi de 3,64% e 2,53% para CQB, 9,09% e 5,65% para CQA e 10,32% e 4,82% para PI, respectivamente. Desta forma, foi possível validar uma técnica para determinação do bussulfano em plasma por HPLC-PDA, adequada à monitorização terapêutica de pacientes.